<DOC>
	<DOCNO>NCT01429350</DOCNO>
	<brief_summary>The purpose trial ass safety effectiveness Penumbra System adjunctive treatment intravenous ( IV ) recombinant human tissue plasminogen activator ( rtPA ) patient acute ischemic stroke large vessel occlusion brain . IV rtPA drug approve treatment acute ischemic stroke work well case stroke cause large vessel occlusion . The hypothesis test determine addition treatment mechanical thrombectomy device like Penumbra System improve clinical outcome patient use IV rtPA alone .</brief_summary>
	<brief_title>Assess Penumbra System Treatment Acute Stroke</brief_title>
	<detailed_description>Current therapy acute stroke limit intravenous administration intravenous ( IV ) recombinant human tissue plasminogen activator ( rtPA ) thrombolysis affect cerebral artery within 3-4.5 hour symptom onset , use intra-arterial ( IA ) endovascular mechanical clot retrieval device within 8 hour ictus , limitation mono therapy . For example , IV rtPA may efficacious large vessel occlusion long term effect mechanical thrombectomy device patient functional outcome unknown . This randomized , concurrent control study ass safety effectiveness Penumbra System adjunctive therapy IV rtPA acute intervention acute ischemic stroke . Patients present symptom acute ischemic stroke evidence large clot burden ( clot length &gt; 8mm ) anterior circulation assign either IV rtPA therapy alone ( 0.9mg/kg maximum 90mg ) combine IV rtPA therapy ( 0.9mg/kg maximum 90mg ) intra-arterial ( IA ) adjunctive treatment Penumbra System . Each treat patient follow assessed 3 month enrollment .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>1 . From 18 85 year age 2 . Present symptom consistent acute ischemic stroke eligible IV rtPA therapy ( patient present 34.5 hrs symptom onset eligible &gt; 80 yrs age , history stroke diabetes , anticoagulant use ( even INR &lt; 1.7 ) NIHSS score &gt; 25 3 . Evidence large vessel occlusion anterior circulation clot length 8mm long 4 . NIH Stroke Scale ( NIHSS ) score 8 great aphasic presentation 5 . Signed informed consent 1 . History stroke past 3 month . 2 . Females pregnant 3 . Preexisting neurological psychiatric disease could confound study result prestroke mRS score 1 great 4 . Known severe allergy contrast medium 5 . Uncontrolled hypertension ( define systolic blood pressure &gt; 185 mmHg diastolic blood pressure &gt; 110 mmHg ) 6 . CT evidence follow condition randomization : Significant mass effect midline shift Any acute ischemic change &gt; 1/3 affected middle cerebral artery territory Evidence intracranial hemorrhage 7 . Angiographic evidence tantem extracranial occlusion arterial stenosis proximal occlusion require treatment prior thrombus removal . Moderate stenosis require treatment exclusion 8 . Angiographic evidence preexist arterial injury 9 . Rapidly improve neurological status prior randomization 10 . Bilateral stroke 11 . Intracranial tumor 12 . Known history cerebral aneurysm arteriovenous malfunction 13 . Known hemorrhagic diathesis , coagulation deficiency , anticoagulant therapy International Normalized Ratio ( INR ) &gt; 1.7 14 . Baseline platelets &lt; 50,000 15 . Use IV heparin past 48 hour PPT &gt; 1.5 time normalized ratio 16 . Pretreatment glucose &lt; 50mg/dL &gt; 300mg/dL 17 . Life expectancy le 90 day prior stroke onset 18 . Participation another clinical investigation could confound evaluation study device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>ischemic stroke</keyword>
	<keyword>acute intervention</keyword>
	<keyword>thrombolysis</keyword>
	<keyword>rtPA</keyword>
	<keyword>internal carotid artery</keyword>
	<keyword>middle cerebral artery</keyword>
	<keyword>mechanical thrombectomy</keyword>
	<keyword>Penumbra System</keyword>
	<keyword>clot length</keyword>
	<keyword>mRS</keyword>
	<keyword>NIHSS</keyword>
</DOC>